ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd
Condition: Breast Cancer
Sponsor: Ambrx, Inc.
Full Title
Protocol ACE-Breast-03: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Study Treatment
HER2 targeting antibody-drug conjugate ARX788
Eligibility/Info
HER2-positive metastatic breast cancer treated with up to 5 prior lines of therapy in the metastatic setting, one of which included trastuzumab deruxtecan.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
